A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

NCT ID: NCT02152332

Last Updated: 2014-11-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 64 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-31
• Study Completion Date: 2014-10-31

Brief Summary

The purpose of this study is to evaluate the effects of JNJ-54861911 on the QT/QTc intervals in healthy participants, when administered at therapeutic (50 milligram [mg] once-daily) and supratherapeutic (150 mg once-daily) doses for 7 days.

Detailed Description

This is a Phase 1, double blind (a medical research study in which neither the researchers nor the participants know what treatment the participants is receiving), randomized (study drug assigned by chance), placebo and positive-controlled, multiple-dose, 4-way crossover (method used to switch participants from one study group to another) study. The study consists of 3 parts: Screening period (Days -21 to -2), Double-blind treatment period and End-of-study/early withdrawal assessment period (9 to 13 days after last dose). Treatment period will comprise of 4 treatment regimens each consisting of a baseline assessment and a treatment regime (Days -1 to 9). The participants will be randomly assigned to 1 of 4 treatment sequence groups (ADBC, BACD, CBDA, and DCAB) based on a computer-generated randomization schedule and will receive the following 4 treatments in the order specified by the randomization: Treatment A (JNJ-54861911, 50 milligram (mg) once daily for 7 days plus moxifloxacin-matched placebo on Day 7); Treatment B (JNJ-54861911, 150 mg once daily for 7 days plus moxifloxacin-matched placebo on Day 7); Treatment C (JNJ-54861911-matched placebo once daily for 7 days plus moxifloxacin-matched placebo on Day 7); Treatment D (JNJ-54861911-matched placebo once daily for 7 days plus moxifloxacin 400 mg on Day 7). Each treatment period will be separated by a washout period of at least 6 - 10 days. Total duration of study for a participant will be 93 days. Change from Baseline in QT/QTc intervals at Day 7 will be evaluated as primary end point. Participant's safety will be monitored throughout the study.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Treatment Sequence Group ADBC

Participant will receive Treatment A (JNJ-54861911, 50 milligram (mg) once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of second treatment regimen, then Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).

Group Type: EXPERIMENTAL

JNJ-54861911-Therapeutic Dose

Intervention Type: DRUG

JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.

JNJ-54861911 - Supratherapeutic Dose

Intervention Type: DRUG

JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.

JNJ-54861911-Matched Placebo

Intervention Type: DRUG

JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.

Moxifloxacin

Intervention Type: DRUG

Moxifloxacin 400 mg on Day 7 in all treatment sequence.

Moxifloxacin Matched Placebo

Intervention Type: DRUG

Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.

Treatment Sequence Group BACD

Participant will receive Treatment B (JNJ-54861911, 150 mg once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of fourth treatment regimen).

Group Type: EXPERIMENTAL

JNJ-54861911-Therapeutic Dose

Intervention Type: DRUG

JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.

JNJ-54861911 - Supratherapeutic Dose

Intervention Type: DRUG

JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.

JNJ-54861911-Matched Placebo

Intervention Type: DRUG

JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.

Moxifloxacin

Intervention Type: DRUG

Moxifloxacin 400 mg on Day 7 in all treatment sequence.

Moxifloxacin Matched Placebo

Intervention Type: DRUG

Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.

Treatment Sequence Group CBDA

Participant will receive Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on second treatment regimen), then Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of third treatment regimen) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).

Group Type: EXPERIMENTAL

JNJ-54861911-Therapeutic Dose

Intervention Type: DRUG

JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.

JNJ-54861911 - Supratherapeutic Dose

Intervention Type: DRUG

JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.

JNJ-54861911-Matched Placebo

Intervention Type: DRUG

JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.

Moxifloxacin

Intervention Type: DRUG

Moxifloxacin 400 mg on Day 7 in all treatment sequence.

Moxifloxacin Matched Placebo

Intervention Type: DRUG

Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.

Treatment Sequence Group DCAB

Participant will receive Treatment D (JNJ-54861911-matched placebo once daily for 7 days plus moxifloxacin 400 mg on Day 7) followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on fourth treatment regimen).

Group Type: EXPERIMENTAL

JNJ-54861911-Therapeutic Dose

Intervention Type: DRUG

JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.

JNJ-54861911 - Supratherapeutic Dose

Intervention Type: DRUG

JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.

JNJ-54861911-Matched Placebo

Intervention Type: DRUG

JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.

Moxifloxacin

Intervention Type: DRUG

Moxifloxacin 400 mg on Day 7 in all treatment sequence.

Moxifloxacin Matched Placebo

Intervention Type: DRUG

Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.

Interventions

JNJ-54861911-Therapeutic Dose

JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.

Intervention Type: DRUG

JNJ-54861911 - Supratherapeutic Dose

JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.

Intervention Type: DRUG

JNJ-54861911-Matched Placebo

JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.

Intervention Type: DRUG

Moxifloxacin

Moxifloxacin 400 mg on Day 7 in all treatment sequence.

Intervention Type: DRUG

Moxifloxacin Matched Placebo

Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.

Intervention Type: DRUG

Other Intervention Names

RSC-385896; MTS-0385896A; RSC-385896; MTS-0385896A

Eligibility Criteria

Inclusion Criteria

• Signed an informed consent document indicating they understand the purpose of and procedures required for the study, including the required pharmacogenomics component (which specifies testing of genes predisposing to long or short QT and related cardiac syndromes), and are willing to participate in the study
• If a woman, must be either a) Not of childbearing potential: postmenopausal (greater than [>] 45 years of age with amenorrhea for at least 2 years, or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone [FSH] >40 international units per milliliter [IU/mL])or surgically sterile; b) Of child-bearing potential and be practicing an effective method of birth control
• If a man, who is sexually active with a woman of child-bearing potential and has not had a vasectomy, must agree to use an adequate contraception method as deemed appropriate by the investigator
• An average of triplicate 12-lead electrocardiogram (ECG) recordings, completed within 4 minutes total, consistent with normal cardiac conduction and function, including: a) normal sinus rhythm with heart rate between 45 and 100 beats per minutes (inclusive); b) QTcF interval between 350 to 450 milliseconds, inclusive; c) QRS interval of less than (<) 110 milliseconds; d) PR interval <200 milliseconds; e) PR interval <200 milliseconds; f) ECG morphology consistent with healthy cardiac conduction and function
• Blood pressure (after the participants remains supine for 5 minutes) between 90 and 140 milimeters of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic

Exclusion Criteria

• History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, infection, gastro-intestinal disease, or any other illness that the investigator considers should exclude the parrticipants or that could interfere with the interpretation of the study results
• History of additional risk factors for torsade de pointes or the presence of a family history of Short QT Syndrome, Long QT Syndrome, abnormal bleeding or blood clotting, sudden unexplained death at a young age (less than/equal to 40 years), drowning or sudden infant death syndrome in a first degree relative (that is, biological parent, sibling, or child)
• Use of any prescription medication (with the exception of hormonal contraceptives or hormonal replacement therapy) within 14 days before Day -1 of Period 1; use of nonprescription medication (including vitamins and herbal supplements such as St. John's Wort) except for acetaminophen, within 30 days before Day -1 of Period 1; acetaminophen within 3 days of study drug administration in each treatment period
• Clinically significant abnormal values for hematology, clinical chemistry (including hypo- or hyperkalemia, -magnesemia, or -calcemia) or urinalysis at Screening or at admission to the study center for Period 1 as deemed appropriate by the Investigator
• Clinically significant abnormal physical examination, vital signs or 12-lead ECG at Screening or at admission to the study center for Period 1 as deemed appropriate by the Investigator

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janssen Research & Development, LLC Clinical Trials

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Tempe, Arizona, United States

Countries

United States

Other Identifiers

54861911ALZ1007

Identifier Type: OTHER

Identifier Source: secondary_id

CR104508

Identifier Type: -

Identifier Source: org_study_id